Alectinib + Bevacizumab: A Dual-Targeted Strike but Cautionary Safety Against ALK-Rearranged NSCLC
- Trial ID
- NCT03779191 on ClinicalTrials.gov
- Cancer type
- Non-Small Cell Lung Cancer
- Published in
- New in Oncology - May 29, 2025
This phase 2 trial (NCT03779191) with 41 patients combines alectinib with bevacizumab in advanced ALK-positive non-small cell lung cancer (NSCLC). The combination achieved a 12-month PFS rate of 97.1% (95% CI 92.6–100), 36-month OS of 87.9%, and ORR of 100%. Discontinuation of bevacizumab was observed in 18 patients (43.9%) due to proteinuria-related events.
Take home
The results suggest that combination treatment significantly improves outcomes with first-line therapy for ALK-rearranged NSCLC, but with very high discontinuation rates, it’s unlikely that this will become a standard of care combination.
Source: Read the original publication
More in non-small cell lung cancer
-
Trial result · Oct 22, 2026 · NCT04905316
Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC -
Trial result · Oct 15, 2026 · NCT04495153
CAN-2409 + valacyclovir reports 14.3-month median OS in treated NSCLC patients; 24.5 months in a selected per-protocol group -
New trial · Oct 15, 2026 · NCT07852247
Phase 1 CyberKnife SBRT uses Synchrony respiratory motion tracking for ultra-central NSCLC -
New trial · Oct 15, 2026 · NCT07617337
Phase 1 AQUA07 allosteric ALK inhibitor (macrocyclic peptide) alone or with lorlatinib in ALK-positive NSCLC -
Trial result · Oct 8, 2026 · NCT03052608
AI volumetric brain-met response may better predict PFS in ALK+ NSCLC